Tulane Cancer Center Members: G
Faculty Membership Application and Membership Definitions
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
------------
Garry, Gitlin, Godbey, Gregory
Robert F. Garry, Ph.D.
Professor of Microbiology & Immunology
Director of MCB Program
TCC Associate Member
rfgarry@tulane.edu
Lab homepage: http://www.Tulane.EDU:80/~dmsander/GarryHomePage.html
Faculty listing on the Microbiology website:
http://www.som.tulane.edu/departments/microbiology/garry.htm
(504) 988-2027, (504) 988-1994 fax
1430 Tulane Ave., Box SL-38, New Orleans, LA 70112-2699

Biographical Narrative:
Dr. Garry received his B.S in Life Sciences with a minor in Chemistry from Indiana State University in 1978. He then carried out doctoral studies in Microbiology at the University of Texas at Austin under the direction of Dr. Marilynn R.F. Waite and received his Ph.D. in 1978. His dissertation was entitled: "Intracellular sodium and potassium and the regulation of gene expression in virus-infected and virus-transformed chick cells." He carried out postdoctoral research in virology at UT Austin under the mentorship of Dr. Henry R. Bose, Jr. In 1983 Dr. Garry was appointed Assistant Professor of Microbiology and Immunology at Tulane University School of Medicine in New Orleans, Louisiana. In 1985 he was Visiting Professor of Pathology at the University of Southern California working with Dr. Suraiya Rasheed. Dr. Garry spent 1991 as a Visiting Professor of Molecular Biology at the University of Hamburg working with Dr. Gebhard Koch. Since 1993 he has been Professor of Microbiology and Immunology at Tulane Medical School. Dr. Garry has published over 100 papers in the area of retrovirology. Research in the Garry Laboratory focuses on a number of aspects of retroviral pathogenesis. Investigations have found that HIV induces a number of defects in plasma membrane ion transport, which could account for the loss of CD4+ T-cells in AIDS patients. Another research interest is the molecular characterization of an isolate of HIV from a patient who died of AIDS in 1969. This is the earliest confirmed case of AIDS in the United States. In addition, the lab has discovered a retrovirus named human intracisternal A-type retroviral particle (HIAP), which appears to be involved in systemic autoimmune diseases and idiopathic CD4 T-lymphocytopenia. More recently, the lab obtained evidence for the existance of a human endogenous retrovirus named human mammary tumor virus (HMTV), which is a close homolog of a virus which causes breast cancer in mice.

Selected Publications:
Melvin C. Gitlin, M.D., F.A.C.P.M.
Professor and Chairman of Anesthesiology
Director of Pain Management Center
TCC Associate Member
mgitlin@tulane.edu
Homepage on the Anesthesiology website:
http://www.som.tulane.edu/anes/Faculty_Bios/Gitlin.htm
(504) 988-1916, (504) 988-1743 fax
1430 Tulane Ave., Box SL-4, New Orleans, LA 70112-2699

Biographical Narrative:
Melvin C. Gitlin, M.D., FACPM, currently serves as Chairman and Merryl and Sam Israel Professor, Department of Anesthesiology, Tulane University School of Medicine, New Orleans, Louisiana. He also serves as the Director of the Pain Management Center of the Tulane University Health Sciences Center and is an Associate Member of the Tulane Cancer Center. He received his medical degree from the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, and received his specialty training at the Department of Anesthesiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. He is a Diplomate of the American Board of Anesthesiologyand also has been certified in pain management by the Board. He has also been designated a Diplomate of the American Board of Pain Medicine. Dr. Gitlin has a long interest and experience in pain management. He is actively engaged in the practice of anesthesiology and pain medicine and is also involved in research. He lectures at the local, regional, national and international levels. He has been widely published and serves as a reviewer for several journals. He is a member of numerous societies and has been very active in the organized pain community for many years; he has served as chairman of numerous committees and task forces. Among other responsibilities, he currently serves as Immediate Past President and member of the Executive Committee, Board of Directors of the American Academy of Pain Medicine and as Treasurer and member of the Executive Committee of the Board of Directors of the Foundation for Pain Medicine. He is a member of the Examination Council and Credentials Committee of the America Board of Pain Medicine. Dr. Gitlin is a member of the Louisiana State Pain commission and is Past Chairman of the Louisiana State Cancer Pain Initiative. He has served as a founding member of the Board of Directors of the American Alliance of Cancer Pain Initiatives. Dr. Gitlin's experience has encompassed both the private and academic sectors and he has served in government.

Selected Publications:
W. T. Godbey, Ph.D.
Assistant Professor of Chemical Engineering and Biomedical Engineering
TCC Contributing Member in Signaling Research Program
godbey@tulane.edu
(504) 865-5872, (504) 865-5744 fax
300 Lindy Boggs Center, Uptown Campus
6823 St. Charles Avenue, New Orleans, LA 70118-5684
Homepage on the Chemical Engineering website:
http://www.tulane.edu/~ceng/Faculty/godbey/Homex.htm
Courses taught
Biographical Narrative:
W.T. Godbey is an Assistant Professor in the Departments of Chemical Engineering and Biomedical Engineering at Tulane University. He received his B.S. in Mathematics from Southern Methodist University in 1988. After a successful period that involved starting his own software design and development company in Dallas, Texas, he joined the fields of science and engineering and earned his Ph.D. as a National Science Foundation Graduate Fellow from the Institute for Biosciences and Bioengineering at Rice University in Houston, Texas, in 2000. From 2000-2003 he was a postdoctoral fellow at Children's Hospital, Boston, and Harvard Medical School. He joined the Tulane faculty in 2003. Gobdey's research interests are centered on gene therapy and the manipulation of cell at the genetic level. He has published several papers on the subjects of cellular processing of non-viral gene delivery agenst and the use of gene therapy for treatment of bladder cancer. His current research interests include the use of gene therapy for carcinoma treatment, controlled release applications for efficient gene delivery, and the use of gene delivery for cellular engineering.

Selected Publications:

Carl Austin Gregory, Ph.D.
Assistant Professor, Department of Medicine/Center for Gene Therapy
TCC Program Member
cgregory@tulane.edu
(504) 988-7176, (504) 988-7710 fax
1430 Tulane Ave., SL-99, New Orleans, LA 70112

 

Biographical Narrative:
Carl Gregory graduated in 1999 with a PhD from the Wellcome Trust Centre for Cell-Matrix Research (University of Manchester, United Kingdom), where he worked in the biochemistry of type X collagen assembly in heritable disorders of the skeleton. There, he was one of the first to propose and substantiate dominant interference as the major cause of the bone development disorder Metaphyseal Chondrodysplasia Type Schmid. Over the past three years,Gregory has studied the role of human mesenchymal stem cells (hMSCs) from bone marrow stroma in bone development and repair in the Tulane University Center for Gene Therapy under the directorship of Darwin Prockop. Carl's recent work has highlighted the importance of Wnt signaling in MSC-mediated bone repair in health and disease. In 2005, Carl was appointed assistant professor in the Department of Medicine at Tulane University Health Sciences Center, where he continues to work in the Center for Gene Therapy.

Selected Publications:

  • Gunn WG, Conley A, Prockop DJ, Gregory CA. A crosstalk between myeloma cells and marrow stromal cells stimulated production of DKK1 and IL-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells, Nov 17, 2005 (epub ahead of print).
  • Gregory CA, Singh H, Perry AS, Prockop DJ. Dkk-1 is required for re-entry into the cell cycle of human adult stem cells from bone marrow stroma (hMSCs). J Biol Chem, 278:28067-78, 2003.
  • Gregory CA, Perry AS, Reyes E, Conley A, Gunn WG, Prockop DJ. Dkk-1 derived synthetic peptides and lithium chloride for the control and recovery of adult stem cells from bone marrow. J Biol Chem, 280:2309-2323, 2004.
  • Gregory CA, Ylostalo J, Prockop DJ. Adult bone marrow stem/progenitor cells (MSCs) are pre-conditioned by micro-environmental "niches" in culture: a two-stage hypothesis for regulation of MSC fate. Sci STKE, 294:37, 2005.


------------
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Return to the top of this page.
Return to the Tulane Cancer Center homepage.

Calendars Clinical Trials Faculty Links Location News
Search Site index
This page is http://www.som.tulane.edu/cancer/TCCnames/facg.html
This page was last updated on
Tulane Cancer Center, Box SL-68
1430 Tulane Avenue
New Orleans, Louisiana 70112-2699
(504) 988-6060, fax (504) 988-6077
http://www.som.tulane.edu/cancer